Regulatory milestones

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) jumped $5.13 (64%) to $13.10 on Thursday after announcing that FDA said existing data, including a single Phase III trial, were sufficient to support an NDA for pimavanserin to treat Parkinson's disease psychosis (PDD). As a result, the company said it will no longer conduct a confirmatory Phase III trial, which was slated to start this month.